טוען...
A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis
EGF-like growth factors control tumor progression, as well as evasion from the toxic effects of chemotherapy. Accordingly, antibodies targeting the cognate receptors, such as EGFR/ErbB-1 and the co-receptor HER2/ErbB-2, are widely used to treat cancer patients, but agents that target the EGF-like gr...
שמור ב:
| Main Authors: | , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3290749/ https://ncbi.nlm.nih.gov/pubmed/22105361 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2011.518 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|